2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sarah Nagle, MD, discusses sequencing challenges in multiple myeloma.
Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses sequencing challenges in multiple myeloma.
Developing an optimal sequencing strategy can be difficult in multiple myeloma considering all the available treatment options, Nagle says.
Currently, the question of whether certain treatments should be utilized up front or reserved for progression remains unanswered, Nagle says. The answer to this question may inform treatment sequencing.
Additionally, some patients who do not respond to novel agents respond to cytotoxic chemotherapy, explains Nagle. As such, identifying these patients earlier will aid in optimizing their treatment course.
Although having a multitude of treatment options is beneficial, utilizing them in the appropriate sequence may remain a significant challenge, concludes Nagle.